Search

D2C7 immunotoxin

D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL.

MB07811

MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. … The combination of selectivity for the beta form of the receptor, liver targeting and other structural characteristics that limit extra-hepatic activity is designed to provide significant efficacy while

Iproclozide

Iproclozide is an irreversible and selective hydrazine class based monoamine oxidase inhibitor (MAOI). … Although it was employed as an antidepressant for a time, the fact that the agent is capable of causing fulminant hepatitis and that its use has been documented as the cause for at least three reported

Briakinumab

Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. … It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha.

APL-9

It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. … APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation.

Cyd dengue virus serotype 1 live (attenuated) antigen

Cyd dengue virus serotype 2 live (attenuated) antigen

Ruplizumab

Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.

Salmon calcitonin

Synthetic peptide, 32 residues long formulated as a nasal spray.

Verubecestat

In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of … 57, 79 and 84 percent, respectively.